Perrigo (NYSE:PRGO) Shares Gap Down – Should You Sell?

Posted by George Bondi on Jun 9th, 2026

Perrigo Company plc (NYSE:PRGO – Get Free Report) shares gapped down before the market opened on Tuesday . The stock had previously closed at $11.61, but opened at $11.00. Perrigo shares last traded at $11.3270, with a volume of 758,489 shares changing hands.

Analyst Upgrades and Downgrades

PRGO has been the topic of a number of research analyst reports. Canaccord Genuity Group dropped their price objective on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Finally, Weiss Ratings lowered shares of Perrigo from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $19.33.

View Our Latest Stock Analysis on Perrigo

Perrigo Stock Performance

The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The company has a market capitalization of $1.54 billion, a PE ratio of -0.85, a price-to-earnings-growth ratio of 1.28 and a beta of 0.51. The firm’s fifty day simple moving average is $11.12 and its 200 day simple moving average is $12.49.

Perrigo (NYSE:PRGO – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The company had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The firm’s revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, research analysts predict that Perrigo Company plc will post 2.12 EPS for the current year.

Perrigo Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th will be given a $0.29 dividend. The ex-dividend date is Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.4%. Perrigo’s dividend payout ratio is -8.85%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Geneos Wealth Management Inc. raised its position in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares during the period. Kestra Investment Management LLC raised its position in shares of Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after acquiring an additional 642 shares during the period. Jones Financial Companies Lllp raised its position in shares of Perrigo by 89.1% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock worth $38,000 after purchasing an additional 838 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after purchasing an additional 1,014 shares during the last quarter. Finally, UMB Bank n.a. raised its position in shares of Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after purchasing an additional 1,213 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Company Profile

(Get Free Report)

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.